Checking body response to lung cancer immunotherapy
Part of Cancer clinical trials.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC).
- Your doctor plans to treat you with a checkpoint inhibitor by itself (not with chemo).
- You have never had a checkpoint inhibitor before.
- You are able to give blood samples.
- You are 18 or older and physically active enough for daily tasks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.